AbbVie says that Elahere is the first and only folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine ...

UK clinical-stage gene specialist Silence Therapeutics (Nasdaq: SLN) yesterday presented end-of-treatment data from its Phase ...

Swiss cancer giant Novartis (NOVN: VX) has entered into an exclusive worldwide licensing and collaboration deal with Ratio ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Monday approved the medicine Filspari (sparsentan) from Vifor France to treat primary immunoglobulin A nephropathy (IgAN).

New York-based ophthalmic technology company Eyenovia is considering its options. Shares in the company dropped by 70% on ...

Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) ...

Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to ...

Junshi Biosciences' Loqtorzi has received MHRA approval for NPC and ESCC, marking the first NPC drug and a PD-L1-independent ...

Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...

French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from ...

Keymed Biosciences has licensed global rights for CM336, excluding Greater China, to Platina Medicines in a deal worth up to ...

New research published by the European Federation of Industries and Associations (EFPIA) provides in-depth analysis of the ...